Sera level and polymorphism of interleukin-33 gene in iraqi females patients with breast cancer

Abstract EN

Interleukin-33 [IL-33] is a specific ligand for the ST2 receptor, and a member of theIL-1 family.

It is a dual-function protein that acts both as an extracellular alarmin cytokine, and an as an intracellular nuclear factor participates in maintaining barrier function byregulating gene expression of IL-33 modulating tumor growth and anti-tumor immunity incancer patients.

The present study aimed to investigate the role of IL-33 serum level and genepolymorphism in Iraqi women with breast cancer.

Materials and methods: Blood sampleswere collected from 66 Iraqi patient women diagnosed with breast cancer, which were dividedinto two groups: pre-treatment [PT] and under treatment with chemotherapy [UTC] patients inaddition to 34 apparently healthy women who were matched with patients as a control.

ELISA technique was used to determine the IL-33 serum level.

The PCR-RFLP techniquewas performed to determine IL-33 gene polymorphisms at single nucleotide polymorphismSNP [rs1929992].

Results: IL-33 serum level recorded lower significant in PT [182.22 ±29.86pg/ml] and UTC [129.87 ± 45.11pg/ml] patients compared with control [258.08 ± 39.54pg/ml] under [p<0.05].

In a polymorphism study on IL-33 SNP [rs1929992] showed AGgenotype recorded the high frequency in control than in patients [76.47, 58.46] compared toother genotypes AA, GG with no significant difference according to fisher's exact probability.

In conclusion: IL-33 serum level decreased after performing surgery on breast cancerpatients.

There was no association between breast cancer development and IL-33 SNP[rs1929992].

The heterozygous genotype AG was a common genotype in the Iraqi population.

Allele G had an environmental fraction, while allele A had preventive fraction, which related to increasing the level of IL-33 with both genotypes AA, AG in the healthy control group, incontrast with GG genotype which showed the highest level in the patients' is a specific ligand for the ST2 receptor, and a member of theIL-1 family.

It is a dual-function protein that acts both as an extracellular alarmin cytokine, and an as an intracellular nuclear factor participates in maintaining barrier function byregulating gene expression of IL-33 modulating tumor growth and anti-tumor immunity incancer patients.

The present study aimed to investigate the role of IL-33 serum level and genepolymorphism in Iraqi women with breast cancer.

Materials and methods: Blood sampleswere collected from 66 Iraqi patient women diagnosed with breast cancer, which were dividedinto two groups: pre-treatment [PT] and under treatment with chemotherapy [UTC] patients inaddition to 34 apparently healthy women who were matched with patients as a control.

ELISA technique was used to determine the IL-33 serum level.

The PCR-RFLP techniquewas performed to determine IL-33 gene polymorphisms at single nucleotide polymorphismSNP [rs1929992].

Results: IL-33 serum level recorded lower significant in PT [182.22 ±29.86pg/ml] and UTC [129.87 ± 45.11pg/ml] patients compared with control [258.08 ± 39.54pg/ml] under [p<0.05].

In a polymorphism study on IL-33 SNP [rs1929992] showed AGgenotype recorded the high frequency in control than in patients [76.47, 58.46] compared toother genotypes AA, GG with no significant difference according to fisher's exact probability.

In conclusion: IL-33 serum level decreased after performing surgery on breast cancerpatients.

There was no association between breast cancer development and IL-33 SNP[rs1929992].

The heterozygous genotype AG was a common genotype in the Iraqi population.

Allele G had an environmental fraction, while allele A had preventive fraction, which related to increasing the level of IL-33 with both genotypes AA, AG in the healthy control group, incontrast with GG genotype which showed the highest level in the patients' group